Time-dependent antagonist-agonist switching in receptor tyrosine kinase-mediated signaling.
Animals
Caseins
/ metabolism
Cell Differentiation
Cell Line
Cell Nucleus
/ metabolism
Epithelial Cells
/ metabolism
Janus Kinase 2
/ metabolism
Ligands
Mice
Models, Biological
Protein Multimerization
Protein Transport
RNA, Messenger
/ genetics
Receptor Protein-Tyrosine Kinases
/ agonists
Receptor, ErbB-4
/ metabolism
STAT5 Transcription Factor
/ metabolism
Signal Transduction
Time Factors
Transcription, Genetic
Global sensitivity
JAK-STAT pathway
RTK signaling
Time-dependent switch
Journal
BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194
Informations de publication
Date de publication:
15 May 2019
15 May 2019
Historique:
received:
02
04
2019
accepted:
15
04
2019
entrez:
17
5
2019
pubmed:
17
5
2019
medline:
21
6
2019
Statut:
epublish
Résumé
ErbB4/HER4 is a unique member of the ErbB family of receptor tyrosine kinases concerning its activation of anti-proliferative JAK2-STAT5 pathway when stimulated by ligand Neuregulin (NRG). Activation of this pathway leads to expression of genes like β-casein which promote cell differentiation. Recent experimental studies on mouse HC11 mammary epithelial cells stimulated by ligand Neuregulin (NRG) showed a time-dependent switching behavior in the β-casein expression. This behavior cannot be explained using currently available mechanistic models of the JAK-STAT pathway. We constructed an improved mechanistic model which introduces two crucial modifications to the canonical HER4-JAK2-STAT5 pathway based on literature findings. These modifications include competitive HER4 heterodimerization with other members of the ErbB family and a slower JAK2 independent activation STAT5 through HER4. We also performed global sensitivity analysis on the model to test the robustness of the predictions and parameter combinations that are sensitive to the outcome. Our model was able to reproduce the time-dependent switching behavior of β-casein and also establish that the modifications mentioned above to the canonical JAK-STAT pathway are necessary to reproduce this behavior. The sensitivity studies show that the competitive HER4 heterodimerization reactions have a profound impact on the sensitivity of the pathway to NRG stimulation, while the slower JAK2-independent pathway is necessary for the late stage promotion of β-casein mRNA transcription. The difference in the time scales of the JAK-dependent and JAK-independent pathways was found to be the main contributing factor to the time-dependent switch. The transport rates controlling activated STAT5 dimer nuclear import and β-casein mRNA export to cytoplasm affected the time delay between NRG stimulation and peak β-casein mRNA activity. This study highlights the effect of competitive and parallel reaction pathways on both short and long-term dynamics of receptor-mediated signaling. It provides robust and testable predictions of the dynamical behavior of the HER4 mediated JAK-STAT pathway which could be useful in designing treatments for various cancers where this pathway is activated/altered.
Sections du résumé
BACKGROUND
BACKGROUND
ErbB4/HER4 is a unique member of the ErbB family of receptor tyrosine kinases concerning its activation of anti-proliferative JAK2-STAT5 pathway when stimulated by ligand Neuregulin (NRG). Activation of this pathway leads to expression of genes like β-casein which promote cell differentiation. Recent experimental studies on mouse HC11 mammary epithelial cells stimulated by ligand Neuregulin (NRG) showed a time-dependent switching behavior in the β-casein expression. This behavior cannot be explained using currently available mechanistic models of the JAK-STAT pathway. We constructed an improved mechanistic model which introduces two crucial modifications to the canonical HER4-JAK2-STAT5 pathway based on literature findings. These modifications include competitive HER4 heterodimerization with other members of the ErbB family and a slower JAK2 independent activation STAT5 through HER4. We also performed global sensitivity analysis on the model to test the robustness of the predictions and parameter combinations that are sensitive to the outcome.
RESULTS
RESULTS
Our model was able to reproduce the time-dependent switching behavior of β-casein and also establish that the modifications mentioned above to the canonical JAK-STAT pathway are necessary to reproduce this behavior. The sensitivity studies show that the competitive HER4 heterodimerization reactions have a profound impact on the sensitivity of the pathway to NRG stimulation, while the slower JAK2-independent pathway is necessary for the late stage promotion of β-casein mRNA transcription. The difference in the time scales of the JAK-dependent and JAK-independent pathways was found to be the main contributing factor to the time-dependent switch. The transport rates controlling activated STAT5 dimer nuclear import and β-casein mRNA export to cytoplasm affected the time delay between NRG stimulation and peak β-casein mRNA activity.
CONCLUSION
CONCLUSIONS
This study highlights the effect of competitive and parallel reaction pathways on both short and long-term dynamics of receptor-mediated signaling. It provides robust and testable predictions of the dynamical behavior of the HER4 mediated JAK-STAT pathway which could be useful in designing treatments for various cancers where this pathway is activated/altered.
Identifiants
pubmed: 31092187
doi: 10.1186/s12859-019-2816-3
pii: 10.1186/s12859-019-2816-3
pmc: PMC6521356
doi:
Substances chimiques
Caseins
0
Ligands
0
RNA, Messenger
0
STAT5 Transcription Factor
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Receptor, ErbB-4
EC 2.7.10.1
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
242Subventions
Organisme : National Cancer Institute
ID : U01 CA227550
Organisme : NCI NIH HHS
ID : U54 CA193417
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA227550
Pays : United States
Organisme : FP7 Ideas: European Research Council
ID : FP7-ICT-2011-9-600841
Organisme : National Cancer Institute
ID : U54 CA193417
Références
J Biol Chem. 2009 Aug 21;284(34):22815-24
pubmed: 19542223
J Biol Chem. 2005 Jun 24;280(25):24175-80
pubmed: 15863494
Expert Opin Drug Discov. 2011 Feb;6(2):185-193
pubmed: 21532939
Cell Signal. 2009 Feb;21(2):212-9
pubmed: 18951974
Genes Dev. 2008 Mar 15;22(6):711-21
pubmed: 18347089
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
pubmed: 16829981
Mol Endocrinol. 2006 Oct;20(10):2355-68
pubmed: 16772529
Sci Signal. 2009 Jun 30;2(77):ra31
pubmed: 19567914
Mol Endocrinol. 2008 Oct;22(10):2307-21
pubmed: 18653779
J Cell Biol. 2004 Nov 8;167(3):469-78
pubmed: 15534001
Breast Cancer Res Treat. 2008 Aug;110(3):493-505
pubmed: 17882547
JAKSTAT. 2013 Jul 1;2(3):e24672
pubmed: 24069559
IET Syst Biol. 2011 Nov;5(6):336-6
pubmed: 22129029
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1028-33
pubmed: 12552139
FEBS Lett. 2003 Jan 16;534(1-3):190-6
pubmed: 12527385
PLoS Med. 2005 Nov;2(11):e313
pubmed: 16187797
Bioinformatics. 2006 Dec 15;22(24):3067-74
pubmed: 17032683
Oncol Res. 2004;14(11-12):589-602
pubmed: 15667000
Cell. 2012 May 11;149(4):780-94
pubmed: 22579283
Am J Pathol. 2009 Nov;175(5):1802-9
pubmed: 19808643
Mol Biol Cell. 2006 Sep;17(9):4118-29
pubmed: 16837552
Proc Math Phys Eng Sci. 2019 Mar;475(2223):20180534
pubmed: 31007544
Mol Syst Biol. 2009;5:239
pubmed: 19156131
Nat Rev Cancer. 2015 Sep;15(9):515-27
pubmed: 26289315
IET Syst Biol. 2019 Aug;13(4):169-179
pubmed: 31318334